Skip to main content

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.

Publication ,  Journal Article
Ganjoo, KN; Robertson, MJ; Fisher, W; Jung, S-H; McClean, J; Huh, SY; Bufill, J; Williams, S; Cripe, LD
Published in: Am J Clin Oncol
April 2005

Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

Duke Scholars

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

April 2005

Volume

28

Issue

2

Start / End Page

169 / 172

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphoma, Follicular
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Humans
  • Gemcitabine
  • Female
  • Deoxycytidine
  • Antimetabolites, Antineoplastic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S.-H., McClean, J., Huh, S. Y., … Cripe, L. D. (2005). A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol, 28(2), 169–172. https://doi.org/10.1097/01.coc.0000144812.74663.d0
Ganjoo, Kristen N., Michael J. Robertson, William Fisher, Sin-Ho Jung, John McClean, Sang Yoon Huh, Jose Bufill, Sheron Williams, and Larry D. Cripe. “A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.Am J Clin Oncol 28, no. 2 (April 2005): 169–72. https://doi.org/10.1097/01.coc.0000144812.74663.d0.
Ganjoo KN, Robertson MJ, Fisher W, Jung S-H, McClean J, Huh SY, et al. A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol. 2005 Apr;28(2):169–72.
Ganjoo, Kristen N., et al. “A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.Am J Clin Oncol, vol. 28, no. 2, Apr. 2005, pp. 169–72. Pubmed, doi:10.1097/01.coc.0000144812.74663.d0.
Ganjoo KN, Robertson MJ, Fisher W, Jung S-H, McClean J, Huh SY, Bufill J, Williams S, Cripe LD. A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. Am J Clin Oncol. 2005 Apr;28(2):169–172.

Published In

Am J Clin Oncol

DOI

EISSN

1537-453X

Publication Date

April 2005

Volume

28

Issue

2

Start / End Page

169 / 172

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Lymphoma, Follicular
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Humans
  • Gemcitabine
  • Female
  • Deoxycytidine
  • Antimetabolites, Antineoplastic